Application of rifampicin soaked vascular prosthesis to the infectious aortic aneurysm.

Application of rifampicin soaked vascular prosthesis to the infectious aortic aneurysm. - Applicaition of the Rifampicin Graft

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs051180033

Enrollment

Registered

2019-01-29

Start date

2019-07-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infectious aneurysm or artificial blood vessel infection after transplantation

Interventions

Method For the sample, dissolve 100 mg of rifampicin powder with stirring in 100 ml of 0.05 M phosphate buffer. Subsequently, add 100 mg of ascorbic acid + 490 mg of sodium chloride (for injection),

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects to be studied should be patients diagnosed as infectious aneurysm or artificial blood vessel infection after artificial blood vessel transplantation.

Exclusion criteria

Exclusion criteria: Patients with history of allergy to rifampicin Patients who could not obtain consent from research

Design outcomes

Primary

Measure	Time frame
Major endpoints: control of infectious symptoms at 12 weeks postoperative Evaluate comprehensively with thermal clinical course, blood test data, CT etc image data	—

Contacts

Public ContactTakuma Kobayashi

University Hospital, Kyoto Prefectural University of Medicine

k-takuma@koto.kpu-m.ac.jp+81-75-251-5752

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026